Organon & Co. · NYSE:OGN
Organon & — Shareholder Meeting (June 2024)
18 slides from Organon &'s shareholder meeting presentation, Jun 4, 2024
Slide 1: 2024 Annual Meeting of Shareholders Agenda
ORGANON & CO. Tuesday, June 4, 2024 2024 Annual Meeting of Shareholders 9:00 AM Eastern Daylight Time PART I • Preliminary Procedural Remarks and Opening of the Polls • Opening Remarks and Introduction of Directors and Attendees Agenda PART II • Call to Order • Statement Regarding the Notice of Meet
Slide 2: Organon Board of Directors
[Organon] Proprietary Organon Board of Directors DIRECTOR NOMINEE NOT STANDING FOR RE-ELECTION Carrie Cox Kevin Ali Robert Essner Alan Ezekowitz, Helene Gayle, Chairman, Organon; Chief Executive Officer, Former Chairman, M.D., Ph.D. Ma. Fatima de M.D., MPH Former CEO and former Organon President and
Slide 3: Executive officers
[Organon] Proprietary Executive officers Kevin Ali Aaron Falcione Susanne Juan Camilo Arjona Joseph Chief Executive Officer Chief Human Fiedler Ferreira, M.D. Morrissey Resources Officer Chief Commercial Head of Research & Head of Manufacturing Officer Development and Chief & Supply Medical Officer
Slide 4: 2024 Annual Meeting of Shareholders Agenda
ORGANON & CO. Tuesday, June 4, 2024 2024 Annual Meeting of Shareholders 9:00 AM Eastern Daylight Time PART I • Preliminary Procedural Remarks and Opening of the Polls • Opening Remarks and Introduction of Directors and Attendees Agenda PART II • Call to Order • Statement Regarding the Notice of Meet
Slide 5: 2024 Organon Annual Meeting of Shareholders
2024 Organon Annual Meeting of Shareholders June 4, 2024
Slide 6: Cautionary Note Regarding Forward-Looking Statements
ORGANON & CO. 2024 Annual Meeting of Shareholders Tuesday, June 4, 2024 9:00 AM Eastern Daylight Time Disclaimer Statement – Cautionary Note Regarding Forward-Looking Statements Except for historical information, this presentation includes “forward-looking statements” within the meaning of the safe
Slide 7: Non-GAAP Information
ORGANON & CO. 2024 Annual Meeting of Shareholders Tuesday, June 4, 2024 9:00 AM Eastern Daylight Time Non-GAAP Information This presentation contains “non-GAAP financial measures,” which are financial measures that either exclude or include amounts that are correspondingly not excluded or included i
Slide 8: 2024 Organon Annual Meeting of Shareholders
2024 Organon Annual Meeting of Shareholders June 4, 2024
Slide 9: FY 2023 highlights
FY 2023 highlights Each Franchise Contributed to Growth $6.3B $3.99 Total Revenue Women’s Diluted EPS 3% growth ex-FX up 3%, ex-FX 1 Health Biosimilars 24% growth ex-FX $294M $1.9B Dividends Paid to Non-GAAP Adjusted EBITDA 2 Established Shareholders Brands 2% growth ex-FX 1. Excluding the impact of
Slide 10: Our vision: To create a better and healthier every day for every woman
Our vision: To create a better and healthier every day for every woman Conditions Affecting Only Women By addressing health maternal and peripartum conditions, conditions that are unique infertility, unintended pregnancy to women or impact her differently, we are igniting our purpose, advancing the
Slide 11: Continuing our momentum in 2023
Continuing our momentum in 2023 9 Business development deals Launched Her Plan is Her Power to completed since launch. build global and local efforts to prevent unplanned pregnancy. Nexplanon – our long-acting reversible contraceptive – moves to market Deployed our global ERP system, well- #1 leader
Slide 12: Q1 2024 highlights
Q1 2024 highlights Each Franchise Contributed to Growth $1.6B $0.78 Total Revenue Women’s Diluted EPS 12% growth ex-FX up 7%, ex-FX 1 Health Biosimilars 46% growth ex-FX $538M Non-GAAP Adjusted Established EBITDA 2 Brands 2% growth ex-FX 1. Excluding the impact of foreign currency 2. For further exp
Slide 13: Organon: Here for her health
“= ORGANON Here for her health
Slide 14: Questions & Answers
Questions & Answers ORGANON Here for her health
Slide 15: Thank you
Thank you ORGANON Here for her health
Slide 16: Appendix A
Appendix A ORGANON Here for her health
Slide 17: Reconciliation of GAAP Net Income to Non-GAAP Adjusted EBITDA
Reconciliation of GAAP Net Income to Non-GAAP Adjusted EBITDA Unaudited, $ mil 2023 Net Income 1,023 Depreciation(1) 118 Amortization 116 Interest expense 527 Taxes on income (350) EBITDA 1,434 Restructuring costs 62 Spin-related costs(2) 254 Manufacturing network costs Other(3) 93 Stock-based compe
Slide 18: Reconciliation of GAAP Net Income to Non-GAAP Adjusted EBITDA
Reconciliation of GAAP Net Income to Non-GAAP Adjusted EBITDA Unaudited, $ in millions Q1-2024 Net Income 201 Depreciation(1) 30 Amortization 33 Interest expense 131 Taxes on income 35 EBITDA 430 Restructuring costs 23 Spin-related costs(2) 49 Manufacturing network costs(3) 10 Other Stock-based comp